These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15534665)

  • 41. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
    Goumas GS
    Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
    J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of omega-3 fatty acids on cardiovascular risk factors in patients with type 2 diabetes mellitus and hypertriglyceridemia: an open study.
    De Luis DA; Conde R; Aller R; Izaola O; González Sagrado M; Perez Castrillón JL; Dueñas A; Romero E
    Eur Rev Med Pharmacol Sci; 2009; 13(1):51-5. PubMed ID: 19364085
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipid management in the geriatric patient.
    Nair AP; Darrow B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
    Gouni-Berthold I; Krone W
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S252-4. PubMed ID: 17139581
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
    Barter PJ; Rye KA
    Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):39-46. PubMed ID: 17717290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Managing the patient with hypertriglyceridemia: a practical approach for nurse practitioners.
    Rankin FM; Cohen JD
    J Am Acad Nurse Pract; 2008 Dec; 20 Suppl 2():1-14; quiz 15. PubMed ID: 19143900
    [No Abstract]   [Full Text] [Related]  

  • 49. [Can cardiovascular events be prevented by raising HDL cholesterol?].
    Langslet G; Reikvam A
    Tidsskr Nor Laegeforen; 2008 Jun; 128(13):1519-23. PubMed ID: 18587459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The association of apolipoprotein B and low density lipoprotein with cardiovascular risk factors in the Thai population.
    Krittayaphong R; Chotinaiwatarakul C; Kangkagate C; Bhuripanyo K; Mahanonda N
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S1-7. PubMed ID: 17722296
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment of hypertriglyceridemia. Current aspects].
    Malaguarnera M; Giugno I; Ruello P; Vinci E; Panebianco MP; Motta M
    Recenti Prog Med; 2000; 91(7-8):379-87. PubMed ID: 10932925
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment.
    Vaverkova H; Frohlich J; Jackuliakova D; Novotny D
    Clin Biochem; 2005 Jun; 38(6):509-13. PubMed ID: 15885228
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Postprandial changes of blood lipid after ordinary Chinese diet and the influencing factors thereof].
    Fu ZF; Liu ML
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(4):260-2. PubMed ID: 19552844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
    Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
    Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M
    Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
    Kastelein JJ
    Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
    Reaven GM
    Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations].
    Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.